GlassScriptPhysician profile
Molly K Smith
NPI 1083633416
$10,626.16
in general payments reported to CMS, 2019-2025
22 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $648 · 2021: $894 · 2022: $1,373 · 2023: $4,242 · 2024: $1,374 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Consulting Fee: $2,366 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873 · Travel and Lodging: $468 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.64 |
| Consulting Fee | $2,366.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.83 |
| Travel and Lodging | $468.04 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,804.63 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $3,268.33 | 2022-2024 | Sotyktu |
| Amgen INC. | $781.78 | 2019-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $697.09 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $360.24 | 2019-2025 | Ebglyss |
| Sun Pharmaceutical Industries INC. | $273.86 | 2020-2025 | Blu-U, Odomzo |
| Leo Pharma INC. | $242.92 | 2019-2025 | Adbry |
| Biofrontera INC. | $185.74 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $175.91 | 2019-2025 | |
| Ucb, INC. | $174.78 | 2020-2024 | Bimzelx |
| Botanix Sb INC | $155.70 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $132.07 | 2019 | |
| Pfizer INC. | $110.53 | 2019-2024 | |
| Genentech USA, INC. | $57.67 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.72 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $38.15 | 2025 | Nemluvio |
| Strata Skin Sciences, INC. | $30.29 | 2019 | |
| Dermira, INC. | $22.75 | 2019 | |
| Springworks Therapeutics, INC. | $19.80 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.32 | 2022 | |
| Dusa Pharmaceuticals, INC. | $14.66 | 2019 | |
| Merck Sharp & Dohme LLC | $13.22 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.